Dasatinib and Enoxaparin sodium (Oksapar 4000 Anti-Xa IU/0.4 ml): interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
Dasatinib-related thrombocytopenia or platelet dysfunction can add to antithrombotic bleeding risk.
Clinical significance and safety
Oksapar 4000 Anti-Xa IU/0.4 ml is an anticoagulant. Dasatinib can cause serious bleeding, and SPRYCEL warns that platelet inhibitors or anticoagulants may further increase hemorrhage risk. The treating team should review the indication, blood counts and bleeding symptoms; do not stop either treatment independently.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.